Skip to main content
Clinical Trials/NCT04084301
NCT04084301
Completed
N/A

Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury

Sahlgrenska University Hospital, Sweden1 site in 1 country100 target enrollmentSeptember 27, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Extracorporeal Circulation; Complications
Sponsor
Sahlgrenska University Hospital, Sweden
Enrollment
100
Locations
1
Primary Endpoint
Renal oxygen delivery and blood flow
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

During open cardiac surgery, cardiopulmonary bypass (CPB) is used to temporarily replace the function of the heart and lungs. Renal ischemia resulting in acute kidney injury is common after cardiac surgery. The renal oxygenation is impaired during CPB, but the oxygenation may be improved by increasing the CPB blood flow. In this randomized study, two CPB flow rates will be compared regarding renal outcome (biomarkers and renal oxygenation/renal blood flow), as well as markers of inflammation and hemolysis. Additionally, urine oxygen tension will be measured during CPB and the early intensive care phase and compared to renal oxygenation. Regional oxygen saturation assessed with near infrared spectroscopy from the brain and kidneys will be monitored during and after surgery.

Registry
clinicaltrials.gov
Start Date
September 27, 2019
End Date
November 1, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Sahlgrenska University Hospital, Sweden
Responsible Party
Principal Investigator
Principal Investigator

Lukas Lannemyr

Specialist of Anesthesia and Intensive care

Sahlgrenska University Hospital, Sweden

Eligibility Criteria

Inclusion Criteria

  • Written, signed informed consent
  • Male and female subjects ≥18 years
  • Left ventricular ejection fraction ≥30 %
  • Estimated GFR ≥30 ml/min using the CKD-EPI equation (Levey 2009)
  • Scheduled open cardiac surgery with CPB
  • Planned normothermia during CPB
  • Expected CPB time \> 60 minutes

Exclusion Criteria

  • Emergency surgery
  • Cardiac transplantation
  • Advanced grown-up congenital heart disease corrections
  • Previous cerebral infarction, verified with computed tomography or magnetic resonance imaging
  • Body mass index \> 32 kg/m2
  • Use of hypothermia \< 32 °C during CPB
  • Inability of the patient to give based opinion
  • In the investigator´s opinion, the patient has a condition that could be adversely affected by study participation

Outcomes

Primary Outcomes

Renal oxygen delivery and blood flow

Time Frame: 6 hours

Renal oxygen delivery during and after cardiopulmonary bypass (CPB)

Biomarkers Nephrocheck

Time Frame: 24 hours

Renal biomarker assay Nephrocheck (IGFBP-7 x TIMP-2) will be analyzed in urine

Biomarker u-NAG

Time Frame: 24 hours

Tubulus injury biomarker N-acetyl-ß-d-glucoseaminidase (NAG) will be analyzed in urine with a spectrophotometric method and corrected for urine creatinine.

Secondary Outcomes

  • Serum creatinine and acute kidney injury (AKI)(48 hours)
  • Inflammation IL-8(24 hours)
  • Inflammation TNFa(24 hours)
  • Inflammation IL-10(24 hours)
  • Inflammation IL-1(24 hours)
  • Inflammation IL-6(24 hours)
  • Hemolysis(24 hours)
  • Erythropoetin(24 hours)
  • Neuroinflammation NF(4 days)
  • Complement activation(24 hours)
  • Kidney function(24 hours)
  • Neuroinflammation Tau(4 days)
  • Renal function(24 hours)

Study Sites (1)

Loading locations...

Similar Trials